Neurocrine Biosciences Inc (NASDAQ: NBIX). Relative to the S&P 500 Composite, Neurocrine Biosciences Inc has both Growth and Value characteristics; its appeal is likely to be to Capital Gain-oriented investors; the perception is that NBIX is normal risk.

Neurocrine Biosciences Inc (NASDAQ: NBIX) BUSINESS Neurocrine Biosciences, Inc. discovers, develops, and commercializes drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. It develops drugs for endometriosis, tardive dyskinesia, […]